CTMX CytomX Therapeutics, Inc. Stock Quote

CTMX [NASD]

Index	-	P/E	-	EPS (ttm)	-1.41	Insider Own	0.70%	Shs Outstand	65.39M	Perf Week	-2.14%
Market Cap	117.80M	Forward P/E	-	EPS next Y	-1.31	Insider Trans	0.00%	Shs Float	64.54M	Perf Month	13.66%
Income	-91.90M	PEG	-	EPS next Q	-0.37	Inst Own	85.60%	Short Float	5.92%	Perf Quarter	-33.94%
Sales	70.70M	P/S	1.67	EPS this Y	-82.90%	Inst Trans	-1.13%	Short Ratio	3.44	Perf Half Y	-59.06%
Book/sh	1.04	P/B	1.76	EPS next Y	16.30%	ROA	-26.10%	Target Price	10.88	Perf Year	-71.09%
Cash/sh	4.08	P/C	0.45	EPS next 5Y	-0.90%	ROE	-91.90%	52W Range	1.50 - 7.53	Perf YTD	-57.74%
Dividend	-	P/FCF	-	EPS past 5Y	4.30%	ROI	-93.70%	52W High	-75.23%	Beta	0.60
Dividend %	-	Quick Ratio	2.60	Sales past 5Y	35.80%	Gross Margin	-	52W Low	23.92%	ATR	0.14
Employees	174	Current Ratio	2.60	Sales Q/Q	6.90%	Oper. Margin	-	RSI (14)	53.48	Volatility	7.49% 7.99%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-43.20%	Profit Margin	-	Rel Volume	0.37	Prev Close	1.83
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 05 AMC	Payout	-	Avg Volume	1.11M	Price	1.87
Recom	1.70	SMA20	3.81%	SMA50	6.18%	SMA200	-53.03%	Volume	352,114	Change	1.91%

Jun-24-22

Initiated

BMO Capital Markets

Outperform

Jan-18-22

Upgrade

Barclays

Underweight → Overweight

Nov-15-21

Initiated

BTIG Research

Buy

$16

May-28-21

Downgrade

Barclays

Equal Weight → Underweight

$9 → $7

Mar-29-21

Initiated

JP Morgan

Overweight

$14

Mar-23-21

Upgrade

Jefferies

Hold → Buy

Sep-22-20

Downgrade

Guggenheim

Buy → Neutral

Jun-01-20

Downgrade

Jefferies

Buy → Hold

$16 → $10

May-14-20

Reiterated

H.C. Wainwright

Buy

$16 → $12

Mar-24-20

Upgrade

Wedbush

Neutral → Outperform

Mar-04-20

Initiated

Barclays

Equal Weight

Nov-20-19

Initiated

Guggenheim

Buy

Nov-11-19

Downgrade

Wedbush

Outperform → Neutral

$25 → $8

Jun-13-19

Initiated

Mizuho

Buy

May-14-19

Initiated

Cantor Fitzgerald

Overweight

$21

Mar-11-19

Initiated

Barclays

Overweight

$16

Nov-26-18

Initiated

Piper Jaffray

Overweight

$22

Oct-15-18

Initiated

Goldman

Neutral

$21

Sep-13-18

Initiated

H.C. Wainwright

Buy

$32

Jun-01-18

Initiated

SunTrust

Buy

$38

Jun-27-22 08:33AM	NeoGenomics (NEO) Surges 6.4%: Is This an Indication of Further Gains? Zacks
Jun-16-22 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jun-01-22 08:00AM	CytomX Therapeutics to Present at Jefferies 2022 Global Healthcare Conference GlobeNewswire
May-26-22 08:00AM	CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors GlobeNewswire
May-07-22 08:11AM	Shareholders in CytomX Therapeutics (NASDAQ:CTMX) are in the red if they invested five years ago Simply Wall St.
May-06-22 10:30PM	CytomX Therapeutics (CTMX) Q1 2022 Earnings Call Transcript Motley Fool
May-05-22 06:25PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Lags Revenue Estimates Zacks -5.85%
04:15PM	CytomX Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update GlobeNewswire
Apr-28-22 08:00AM	CytomX Therapeutics to Report First Quarter 2022 Financial Results on May 5, 2022 GlobeNewswire
Apr-14-22 04:15PM	CytomX Therapeutics Announces Retirement of John A. Scarlett, M.D. from Board of Directors GlobeNewswire
Apr-06-22 06:47AM	What Kind Of Shareholders Hold The Majority In CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares? Simply Wall St.
Mar-23-22 04:15PM	CytomX Therapeutics Announces Retirement of Frederick W. Gluck from Board of Directors GlobeNewswire
Mar-17-22 08:00AM	CytomX Therapeutics to Present Updated Preclinical Data for Conditionally Activated Cytokine Program at AACR Annual Meeting 2022 GlobeNewswire +15.67%
Mar-02-22 01:00AM	CytomX Therapeutics (CTMX) Q4 2021 Earnings Call Transcript Motley Fool +14.12%
Mar-01-22 05:45PM	CytomX Therapeutics (CTMX) Reports Q4 Loss, Lags Revenue Estimates Zacks -7.57%
04:15PM	CytomX Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Business Update GlobeNewswire
Feb-28-22 05:15PM	Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates Zacks
08:00AM	CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference GlobeNewswire
Feb-22-22 08:00AM	CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022 GlobeNewswire
Feb-16-22 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Feb-07-22 09:00AM	CytomX Therapeutics Announces Promotion of Amy C. Peterson, M.D. to President and Chief Operating Officer GlobeNewswire
Feb-05-22 08:05AM	Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Invest In Growth? Simply Wall St.
Jan-26-22 08:15AM	Myovant Sciences (MYOV) Reports Q3 Loss, Misses Revenue Estimates Zacks
Jan-20-22 10:41AM	CytomX (CTMX) Gets FDA Nod to Begin Study in Solid Tumors Zacks
08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jan-19-22 08:00AM	CytomX Therapeutics Announces FDA Clearance of Investigational New Drug Application for CX-904 for the Treatment of Advanced Solid Tumors GlobeNewswire +6.53%
Jan-10-22 08:21AM	10 Small-Cap Stocks to Buy According to Billionaire Steve Cohen Insider Monkey
Jan-05-22 08:00AM	CytomX Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-27-21 06:56AM	Is CytomX Stock a Buy Following Disappointing Cancer Therapy Results? Analyst Weighs In TipRanks
Dec-21-21 12:12PM	Why CytomX Therapeutics Stock Is Crashing Today Motley Fool -40.00%
07:53AM	CytomX Posts Interim Data From Phase 2 Trial Of CD71-Targeting Cancer Candidate Benzinga
Dec-20-21 04:05PM	CytomX Therapeutics Announces Preliminary Results for Ongoing Phase 2 Expansion Study of CX-2029, a First-in-Class Antibody-Drug Conjugate Candidate Targeting the Transferrin Receptor, CD71 GlobeNewswire
Nov-17-21 10:01AM	Implied Volatility Surging for CytomX Therapeutic (CTMX) Stock Options Zacks
Nov-11-21 08:00AM	CytomX Therapeutics to Present at Upcoming November Investor Conferences GlobeNewswire
Nov-07-21 07:31AM	Even after rising 11% this past week, CytomX Therapeutics (NASDAQ:CTMX) shareholders are still down 56% over the past three years Simply Wall St.
Nov-05-21 07:30AM	CytomX Therapeutics, inc (CTMX) Q3 2021 Earnings Call Transcript Motley Fool +10.37%
Nov-04-21 06:05PM	CytomX Therapeutics (CTMX) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:15PM	CytomX Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Nov-01-21 08:00AM	CytomX Therapeutics to Present Preclinical Data for Conditionally Activated Cytokine Platform at Society for Immunotherapy of Cancer Annual Meeting GlobeNewswire
Oct-28-21 03:05PM	CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks +8.39%
08:00AM	CytomX Therapeutics to Announce Third Quarter 2021 Financial Results on November 4, 2021 GlobeNewswire
Oct-18-21 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Oct-04-21 08:00AM	CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors GlobeNewswire
Sep-16-21 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Sep-07-21 08:00AM	CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference GlobeNewswire
Aug-17-21 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Aug-09-21 02:40AM	Is CytomX Therapeutics (NASDAQ:CTMX) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Aug-07-21 11:30AM	CytomX Therapeutics, inc (CTMX) Q2 2021 Earnings Call Transcript Motley Fool
Aug-05-21 05:35PM	CytomX Therapeutics (CTMX) Reports Q2 Loss, Misses Revenue Estimates Zacks
04:15PM	CytomX Therapeutics Announces Second Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
Aug-04-21 08:00AM	CytomX Therapeutics Announces Multiple Publications on Pacmilimab (CX-072), a Conditionally Activated Inhibitor of Programmed Death-Ligand 1 (PD-L1) GlobeNewswire
Aug-02-21 08:00AM	CytomX Therapeutics to Present at Upcoming August Investor Conferences GlobeNewswire
Jul-29-21 03:04PM	CytomX Therapeutics (CTMX) Expected to Beat Earnings Estimates: Should You Buy? Zacks
08:00AM	CytomX Therapeutics to Announce Second Quarter 2021 Financial Results on August 5, 2021 GlobeNewswire
Jul-14-21 10:00AM	Here's Why CytomX Therapeutics (CTMX) is Poised for a Turnaround After Losing 15.8% in 4 Weeks Zacks
Jun-21-21 08:00AM	CytomX Therapeutics Announces Publication of First-in-Human Data for CX-2029 in Clinical Cancer Research GlobeNewswire
Jun-10-21 01:17AM	It's Unlikely That The CEO Of CytomX Therapeutics, Inc. (NASDAQ:CTMX) Will See A Huge Pay Rise This Year Simply Wall St.
May-27-21 08:00AM	CytomX Therapeutics to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-21-21 03:01AM	What You Need To Know About CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Investor Composition Simply Wall St.
May-08-21 01:30PM	CytomX Therapeutics, Inc. (CTMX) Q1 2021 Earnings Call Transcript Motley Fool
May-06-21 06:05PM	CytomX Therapeutics (CTMX) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:15PM	CytomX Therapeutics Announces First Quarter 2021 Financial Results and Provides Business Update GlobeNewswire
03:15PM	CytomX Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Apr-29-21 08:00AM	CytomX Therapeutics to Announce First Quarter 2021 Financial Results on May 6, 2021 GlobeNewswire
Apr-14-21 04:01PM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire +5.71%
11:42AM	JPMorgan: 2 Stocks for Stellar Long-Term Gains TipRanks
Mar-24-21 08:00AM	CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021 GlobeNewswire -9.59%
Mar-02-21 12:00PM	CytomX Therapeutics (CTMX) Upgraded to Buy: What Does It Mean for the Stock? Zacks
05:58AM	Moving Average Crossover Alert: CytomX Therapeutics (CTMX) Zacks
Feb-25-21 09:01AM	CytomX Therapeutics, Inc. (CTMX) Q4 2020 Earnings Call Transcript Motley Fool
Feb-24-21 04:15PM	CytomX Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update GlobeNewswire
Feb-23-21 10:25AM	A Preview Of CytomX Therapeutics's Earnings Benzinga -5.65%
Feb-22-21 08:00AM	CytomX Therapeutics to Present at Upcoming March Virtual Investor Conferences GlobeNewswire
Feb-20-21 02:44AM	We're Not Worried About CytomX Therapeutics' (NASDAQ:CTMX) Cash Burn Simply Wall St.
Feb-19-21 08:00AM	CytomX Therapeutics Announces New Employment Inducement Grant GlobeNewswire
Feb-17-21 08:00AM	CytomX Therapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021 GlobeNewswire
Feb-04-21 08:00AM	CytomX Therapeutics to Present at Guggenheim Healthcare Talks 2021 Oncology Day GlobeNewswire
Feb-03-21 08:19AM	UPDATE - CytomX Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
08:00AM	CytomX Therapeutics Announces Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jan-26-21 08:00AM	CytomX Therapeutics Announces Closing of Public Offering of Common Stock GlobeNewswire
Jan-20-21 09:50PM	CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock GlobeNewswire
Jan-19-21 04:35PM	CytomX Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +6.94%
08:00AM	CytomX Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jan-07-21 08:00AM	CytomX Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-20 10:10AM	Is CTMX A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-22-20 04:05PM	CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors GlobeNewswire
12:58AM	Would Shareholders Who Purchased CytomX Therapeutics' (NASDAQ:CTMX) Stock Three Years Be Happy With The Share price Today? Simply Wall St.
Dec-03-20 08:00AM	CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium GlobeNewswire
Nov-11-20 04:01PM	CytomX Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire
Nov-07-20 08:40AM	CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Released Its Third-Quarter Earnings: Here's What Analysts Think Simply Wall St.
Nov-06-20 03:01PM	CytomX Therapeutics, Inc. (CTMX) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 08:00PM	CytomX Therapeutics (CTMX) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:15PM	CytomX Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
04:15PM	CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update GlobeNewswire
08:00AM	CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate GlobeNewswire
Oct-29-20 12:34PM	CytomX Therapeutics (CTMX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Zacks
08:00AM	CytomX Therapeutics to Announce Third Quarter 2020 Financial Results GlobeNewswire
Oct-09-20 08:32AM	What We Learned About CytomX Therapeutics' (NASDAQ:CTMX) CEO Compensation Simply Wall St.
Oct-06-20 05:41PM	Hedge Funds Are Bullish On CytomX Therapeutics, Inc. (CTMX) Insider Monkey
04:10PM	CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D. GlobeNewswire

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McCarthy Sean A.	President and CEO	May 09	Option Exercise	0.94	90,931	85,930	265,853	May 11 04:51 PM
McCarthy Sean A.	President and CEO	Aug 11	Option Exercise	1.13	92,113	104,447	99,922	Aug 13 05:22 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience